XTX Topco Ltd Takes $234,000 Position in Organogenesis Holdings Inc. (NASDAQ:ORGO)

XTX Topco Ltd acquired a new stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 73,172 shares of the company's stock, valued at approximately $234,000. XTX Topco Ltd owned 0.06% of Organogenesis as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the company. Assenagon Asset Management S.A. increased its position in shares of Organogenesis by 54.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company's stock valued at $9,443,000 after buying an additional 1,035,120 shares in the last quarter. State Street Corp raised its holdings in Organogenesis by 0.6% during the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company's stock worth $4,175,000 after buying an additional 9,090 shares during the period. Renaissance Technologies LLC lifted its stake in Organogenesis by 31.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,073,500 shares of the company's stock valued at $3,435,000 after buying an additional 255,600 shares in the last quarter. Norges Bank bought a new stake in shares of Organogenesis during the fourth quarter worth $1,543,000. Finally, Bank of New York Mellon Corp lifted its position in Organogenesis by 35.5% in the 4th quarter. Bank of New York Mellon Corp now owns 418,820 shares of the company's stock valued at $1,340,000 after acquiring an additional 109,762 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Michael Joseph Driscoll sold 25,000 shares of Organogenesis stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total transaction of $127,500.00. Following the completion of the sale, the director now directly owns 166,879 shares of the company's stock, valued at approximately $851,082.90. This trade represents a 13.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 36.90% of the company's stock.

Organogenesis Stock Up 6.9 %

NASDAQ ORGO traded up $0.34 during trading hours on Friday, hitting $5.30. 1,020,988 shares of the company traded hands, compared to its average volume of 1,139,577. Organogenesis Holdings Inc. has a twelve month low of $2.21 and a twelve month high of $6.71. The stock has a market capitalization of $672.70 million, a price-to-earnings ratio of -88.45 and a beta of 1.79. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The business's 50-day moving average is $4.59 and its 200-day moving average is $3.83.

Analysts Set New Price Targets

Separately, Morgan Stanley boosted their price target on Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.